Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Restless Legs Syndrome Clear all
Completed Phase 2 Interventional

A Double Blind Crossover Trial of Levetiracetam (Keppra®) and Placebo in the Treatment of Restless Legs Syndrome (RLS)

NCT00247364
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Levetiracetam (Keppra)
Drug
Lead sponsor
Sleep Health Centers
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2005 · Synced Jul 21, 2026, 11:57 AM EDT
Not listed Not applicable Interventional

The Effect of Magnesium Citrate Supplementation in Restless Legs Syndrome (RLS)

NCT04462796
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Magnesium Citrate
Dietary Supplement
Lead sponsor
OSF Healthcare System
Other
Eligibility
18 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Jul 21, 2026, 11:57 AM EDT
Terminated Phase 3 Interventional Results available

A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome

NCT03992196
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine 1 mg/24 h, Rotigotine 2 mg/24 h, Rotigotine 3 mg/24 h
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
13 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2023 · Synced Jul 21, 2026, 11:57 AM EDT
Not yet recruiting Not applicable Interventional

The Effect of Dry Needling With Electrical Stimulation on Individuals With Restless Legs Syndrome

NCT05860751
View directory record Official record
Conditions
Neck Pain
Interventions
Dry Needling with electrical stimulation
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Jul 21, 2026, 11:57 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS)

NCT01521663
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
IPX159, Placebo
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
38
States / cities
Brimingham, Alabama • Little Rock, Arkansas • La Jolla, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Jul 21, 2026, 11:57 AM EDT
Completed Phase 2 Interventional Results available

Intravenous Iron Metabolism in Restless Legs Syndrome

NCT00685815
View directory record Official record
Conditions
Restless Legs
Interventions
Ferric Carboxymaltose (FCM), Placebo
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Jul 21, 2026, 11:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comprehensive Police Fatigue Management Program

NCT00246051
View directory record Official record
Conditions
Sleep Disorders, Sleep Apnea, Obstructive, Restless Legs Syndrome, Sleep Disorders, Circadian Rhythm, Sleep Initiation and Maintenance Disorders
Interventions
Sleep Hygiene Education, Expert-Led Sleep Disorders Screening and Treatment, Online Sleep Disorders Screening
Behavioral · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
683 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2013 · Synced Jul 21, 2026, 11:57 AM EDT
Terminated Phase 2 Interventional Results available

Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemia

NCT02826681
View directory record Official record
Conditions
Restless Legs Syndrome (RLS)
Interventions
Injectafer® (Ferric Carboxymaltose - FCM), Placebo (Normal Saline)
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
8
States / cities
Lemon Grove, California • Fort Myers, Florida • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Jul 21, 2026, 11:57 AM EDT
Completed Phase 2 Interventional Results available

Simulated Driving Study in Restless Legs Syndrome

NCT01332318
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
XP13512, Diphenhydramine, Placebo
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
21 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Jul 21, 2026, 11:57 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Altered Brain GABA and Glutamate in Restless Legs Syndrome

NCT01109537
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 6, 2015 · Synced Jul 21, 2026, 11:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Spinal Cord Stimulation for Restless Legs Syndrome

NCT03539081
View directory record Official record
Conditions
Restless Legs Syndrome, Neuropathic Pain
Interventions
Dual-energy X-ray absorptiometry Scan, Laboratory Measurements, Blood Flow Measurement, Continuous Blood Pressure, Partial pressure of oxygen, Microneurography, Anthropometric Measurements, John Hopkins Restless Legs Severity Scale, Continuous Blood Pressure Diary
Diagnostic Test · Other · Behavioral
Lead sponsor
Marshall Holland
Other
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Jul 21, 2026, 11:57 AM EDT
Recruiting Not applicable Interventional

Peroneal Electrical Nerve Stimulation in Pregnancy for Restless Legs Syndrome

NCT07144631
View directory record Official record
Conditions
Restless Leg Disorder, Restless Leg Syndrome (RLS), Pregnancy, Sleep Disorder (Disorder)
Interventions
Peroneal Nerve Stimulation (PNS) Device
Device
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jul 21, 2026, 11:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist

NCT03218969
View directory record Official record
Conditions
Restless Legs Syndrome, Augmentation
Interventions
Ecopipam, Placebo
Drug
Lead sponsor
William Ondo, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jul 21, 2026, 11:57 AM EDT
Completed Phase 3 Interventional Results available

Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)

NCT00256854
View directory record Official record
Conditions
Restless Legs Syndrome, Restless Legs Syndrome (RLS)
Interventions
Ropinirole IR 1 mg, Ropinirole IR 2 mg, Ropinirole IR 1 mg Placebo, Ropinirole IR 2 mg Placebo, Ropinirole CR 2 mg, Ropinirole CR 3 mg, Ropinirole CR 2 mg Placebo, Ropinirole CR 3 mg Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
30
States / cities
Laguna Hills, California • Oxnard, California • Pasadena, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Jul 21, 2026, 11:57 AM EDT
Not listed Phase 4 Interventional

An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS

NCT02560766
View directory record Official record
Conditions
RLS
Interventions
HORIZANT 300 mg, HORIZANT 600 mg, Placebo
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
12
States / cities
Redwood City, California • Gulf Breeze, Florida • Winter Park, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Jul 21, 2026, 11:57 AM EDT
Completed Phase 4 Interventional Results available

Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study

NCT01668667
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
GSK1838262 600 mg, GSK1838262 450 mg, GSK1838262 300 mg, GSK1838262 Placebo match
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
42
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated May 23, 2021 · Synced Jul 21, 2026, 11:57 AM EDT
Terminated Not applicable Interventional

REST Study (CompRESsion Therapy for RLS)

NCT03852771
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Cirvo(TM) therapy
Device
Lead sponsor
Radial Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Alameda, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2020 · Synced Jul 21, 2026, 11:57 AM EDT
Completed Phase 3 Interventional

An Extension Trial to Investigate Long-Term Treatment With Transdermal Rotigotine in Idiopathic Restless Legs Syndrome

NCT00263068
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
279 participants
Timeline
2005 – 2007
U.S. locations
1
States / cities
RTP, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Jul 21, 2026, 11:57 AM EDT
Completed Phase 2 Interventional Results available

Dose-Response and Pharmacokinetics of Gabapentin Enacarbil (GEn [XP13512 / GSK1838262]) in Restless Legs Syndrome

NCT01332305
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
GEn (XP13512/GSK1838262), Placebo
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2013 · Synced Jul 21, 2026, 11:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of Tyrosine in Restless Legs Syndrome

NCT01494766
View directory record Official record
Conditions
Restless Legs Syndrome (RLS)
Interventions
L-Tyrosine
Dietary Supplement
Lead sponsor
Seton Healthcare Family
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Jul 21, 2026, 11:57 AM EDT
Completed Phase 2 Interventional

The Effects of Aplindore on the Treatment of Signs and Symptoms of Restless Legs Syndrome

NCT00626418
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Aplindore, Placebo
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
5
States / cities
Hallandale, Florida • Atlanta, Georgia • Crestview Hills, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2011 · Synced Jul 21, 2026, 11:57 AM EDT
Withdrawn Not applicable Interventional

Vasculaire Leg Compression Device for the Treatment of Restless Legs Syndrome - A Prospective Clinical Study

NCT01861652
View directory record Official record
Conditions
Restless Legs Syndrome,, Restless Legs,, Ekbom Syndrome
Interventions
Venous Health Systems Vasculaire Leg Compression Device
Device
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2015 · Synced Jul 21, 2026, 11:57 AM EDT
Completed Phase 2 Interventional

Probiotics in the Treatment of Iron Deficiency in Children With Restless Leg Syndrome

NCT01617044
View directory record Official record
Conditions
Iron Deficiency, Restless Leg Syndrome
Interventions
Probiotics, Placebo
Dietary Supplement
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
5 Years to 18 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 19, 2016 · Synced Jul 21, 2026, 11:57 AM EDT
Not listed Phase 4 Interventional

Sublingual Apomorphine in Refractory Restless Legs Syndrome

NCT05529095
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Apomorphine Sublingual Film, Placebo
Drug
Lead sponsor
William Ondo, MD
Other
Eligibility
21 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2022 · Synced Jul 21, 2026, 11:57 AM EDT